Sign in
Taking peoplePhase 3

Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

Key facts

Who runs it
Nanjing First Hospital, Nanjing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
612 people, planned
Started
15 Jul 2026
Expected to end
30 Dec 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Minocycline
  • Keverprazan
  • Amoxicillin
  • Colloidal Bismuth Pectin
Record updated
5 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age 18-65 years
  • Positive H. pylori status confirmed by 13C-urea breath test and no prior history of eradication therapy
  • Voluntary participation and provision of written informed consent

Who cannot take part

  • Prior history of H. pylori eradication treatment
  • Use of antibiotics or bismuth agents within 4 weeks before treatment initiation, or use of proton pump inhibitors within 2 weeks
  • Current use of corticosteroids, nonsteroidal anti-inflammatory drugs, or anticoagulants
  • Concurrent use of specific medications: atazanavir or rilpivirine, tricyclic antidepressants, levodopa, acetaminophen, guaifenesin/dextromethorphan, monoamine oxidase inhibitors, tramadol, or similar agents
  • Allergy to any study medication (e.g., minocycline, keverprazan, amoxicillin)
  • Confirmed active peptic ulcer disease
  • History of esophageal or gastric surgery
  • Severe comorbidities, including hepatic, cardiovascular, pulmonary, or renal disease
  • Gastric mucosa-associated lymphoid tissue lymphoma, malignant tumors, peptic ulcer disease, or bronchial asthma
  • Pregnancy or lactation
  • Alcohol abuse

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the incidence of adverse drug reactions.

The 3 groups in the trial

  • 10-day dual therapyTreatment being tested

    Treatment: Minocycline and Keverprazan

  • 14-day dual therapyTreatment being tested

    Treatment: Minocycline and Keverprazan

  • 14-day quadruple therapyExisting treatment, for comparison

    Treatment: Minocycline, Keverprazan, Amoxicillin, and Colloidal Bismuth Pectin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Keverprazan-minocycline Dual Therapy With Different Treatment Durations Versus Bismuth-based Quadruple Therapy for Helicobacter Pylori Eradication: an Open-label, Multicenter, Randomized, Non-inferiority Trial.
Criteria questions
Built from NCT07904429, who can take part
Record updated
5 November 2026